This work demonstrated that GLP-1RA treatment was associated with a significant 29% reduction in MALOs compared to non-use (IRR: 0.71, 95%CI: 0.57-0.88, P = 0.003) over a median follow-up of approximately 70,045 patient-years
If you have been following the news lately, you know that GLP-1 medications like semaglutide have fundamentally changed how we treat chronic weight management
How long is the proposed treatment course, and what are the criteria for stopping
If any side effects persist or cause concern, contact your medical provider for guidance
Yes- RDs and Pharmacists are essential in managing these side effects, given GI side effects are the primary reason people discontinue in year one
They are sold in the form of pills, capsules or wafers